Nilvadipine in mild to moderate Alzheimer disease A randomised controlled trial. /
BACKGROUND: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2018
|
| Sorozat: | PLOS MEDICINE
15 No. 9 |
| doi: | 10.1371/journal.pmed.1002660 |
| mtmt: | 3426533 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/15455 |